Media Coverage

Why Did I Choose Toxicology?

03/10/2015

Five toxicologic pathologists offer their perspectives on the benefits and challenges of forging a career in toxicology.

Jump Starting the Non-Profit Research Engine

01/29/2015

While the process of drug discovery remains constant, the groups driving the scientific innovation now include those typically associated with fund-raising, lobbying and patient advocacy. Along with biopharmaceutical companies, which have been at the helm of drug discovery for years, one finds an increasing number of not-for-profit disease foundations angling for a seat at the lab bench.

Advances in PCR Improve Health of Animal Research Colonies

01/22/2015

While challenges remain, PCR-based strategies for direct testing of quarantined rodents and for monitoring dust can replace, reduce or refine the use of sentinel mice in the infectious screening process, supporting the 3R philosophy while greatly improving the detection of rodent infectious agents to help keep animal colonies safe.

James Foster Interview on Mad Money with Jim Cramer

01/14/2015

Live from the JP Morgan Healthcare Conference, James Foster, chairman and CEO at Charles River Laboratories spoke with Mad Money on CNBC. James Foster and Jim Cramer discuss the company’s strategic focus on helping accelerate drug discovery and development.  

On the Hunt Against Huntington’s Disease

12/15/2014

CHDI Foundation, Inc. has extended its ongoing collaboration with Charles River Laboratories for discovering novel drugs for Huntington's disease for an additional five years.

Development of a Viral Induction Study for Cell Bank Characterization

11/15/2014

An approach to consider for detecting latent or endogenous viruses in cell substrates is the use of assays that employ specific chemical compounds to induce virus expression or replication. Following induction, latent and endogenous viruses can then be detected through subsequent assays, such as TEM and QF-PCR testing.

Ready, Aim, CRISPR (or RNAi)

11/15/2014

When targeting genes, drug developers may opt for knockdown via CRISPR or silencing via RNAi. These weapons, however, may fit different battle plans.

Overcoming Cell Line Complacency

11/15/2014

Don’t fall into the cell line misidentification trap. Authenticate! What you don’t know–or what you refuse to acknowledge–will hurt you.

Charles River's Early Drug Discovery Business and CHDI Foundation Extend Huntington's Disease Collaboration

11/07/2014

Today, Charles River Laboratories announced that CHDI Foundation, Inc. has extended its ongoing collaboration for an additional five years. The collaboration, which began in 2005, is focused on discovering novel drugs for Huntington's disease. CHDI has expanded the collaboration with Charles River due to its neuroscience expertise and comprehensive integrated drug discovery capability.

Displaying results 1-10 (of 53)
 |<  < 1 - 2 - 3 - 4 - 5 - 6  >  >|